Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.59 |
| ▸ | FAAH | O00519 | 6/20 | 0.57 |
| ▸ | NAAA | Q02083 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.55 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.51 |
| ▸ | SELP | P16109 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3810356 | 0.95 | CASP2 (0.65) | CASP2FAAHNAAAEPHX2DNM1 | |
| SCHEMBL4458201 | 0.90 | FAAH (0.61) | CASP2FAAHNAAAEPHX2DNM1 | |
| SCHEMBL14994265 | 0.89 | NAAA (0.63) | CASP2FAAHNAAAEPHX2DNM1 | |
| SCHEMBL8148507 | 0.89 | NAAA (0.63) | CASP2FAAHNAAAEPHX2DNM1 | |
| SCHEMBL5962432 | 0.89 | FAAH (0.59) | CASP2FAAHNAAAEPHX2DNM1 | |
| SCHEMBL5962585 | 0.86 | FAAH (0.63) | CASP2FAAHNAAAEPHX2DNM1 | |
| SCHEMBL5962508 | 0.86 | FAAH (0.63) | CASP2FAAHNAAAEPHX2DNM1 | |
| SCHEMBL5398678 | 0.86 | SELP (0.66) | FAAHNAAADNM1MEN1KMT2A | |
| SCHEMBL2800347 | 0.85 | FAAH (0.71) | CASP2FAAHNAAAEPHX2DNM1 | |
| SCHEMBL19066845 | 0.85 | FAAH (0.71) | CASP2FAAHNAAAEPHX2DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014200363-A1 | SPHINGOGLYCOLIPID ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2014-12-18 | — | — | WO | disclosed |
| US-7029671-B1 | Method for activating human antigen-presenting cells, activated human antigen-presenting cells, and use thereof | KIRIN BREWERY COMPANY, LIMITED (JP) | 2006-04-18 | — | — | US | disclosed |
| US-20060073122-A1 | Method for activating human antigen presenting cells, activated human antigen - presenting cells, and use thereof | KIRIN BREWERY COMPANY, LIMITED | 2006-04-06 | — | — | US | disclosed |
| US-6555372-B1 | Viricides and antitumor agents | KIRIN BEER KABUSHIKI KAISHA (JP) | 2003-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060073122-A1 | Method for activating human antigen presenting cells, activated human antigen - presenting cells, and use thereof | CD69, CD14, NFATC1 | CASP2 1557/4885FAAH 1879/4885NAAA 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.